Alphamab Oncology doses first patient in Phase II JSKN033 cervical cancer trial

• Alphamab Oncology dosed first patient in Phase II study JSKN033-202 testing JSKN033 with platinum-based chemotherapy, with optional bevacizumab, as first-line treatment for advanced cervical cancer.
• No new trial results were presented; study will evaluate safety, activity, and drug behavior to support potential move into earlier-line use.
• Program targets a first-line market where standard immunotherapy-based combinations leave a subset of patients with inadequate responses, positioning JSKN033 as a potential alternative built around subcutaneous dosing convenience.
• Company cited earlier-stage studies in previously treated cervical cancer showing encouraging activity with manageable safety, providing rationale for the first-line combination trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260513-12156971), on May 13, 2026, and is solely responsible for the information contained therein.